FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $402.8M
Company Location Date Amt. (M) Details

Abcellute Ltd. Cardiff, UK 12/12** £0.4 ($0.817) Abcellute raised $816,717 through a private financing
ACE Biosciences A/S Odense, Denmark 12/26** €11.9 ($17.1) ACE raised $17.1M in a new investment round
Agile BioPharma Inc. Princeton, N.J. 12/20 $5.6 Agile raised $5.6M in an extension of its Series E financing round, bringing the total of the round to $17.6M; investors were the Hillman Company, ProQuest Investment, TL Ventures and Novitas Capital
Ascendis Pharma A/S Copenhagen, Denmark 12/13 DKK17.6 ($25.7) Ascendis raised $25.7M in a Series A round led by Sofinnova Partners and co-led by Gilde Healthcare Partners, with participation by Zweite TechnoStart Ventures Fonds GmbH & Co. KG
Asuragen Inc. Austin, Texas 12/10 $18.5 Asuragen raised $18.5M in a Series B round; investors included PTV Sciences, Telegraph Hill Partners and Growth Capital Partners
Carigent Therapeutics Inc. New Haven, Conn. 12/11 $2 Carigent secured $2M in a Series A financing from Saint Simeon Marketing and Investments
Cogentus Pharmaceuticals Inc. Menlo Park, Calif. 12/20 $62.5 Cogentus raised $62.5M to support development of its antiplatelet therapy CGT-2168; the Series C financing was led by the Keffi Group, with participation from Prospect Venture Partners, Ridgeback Capital, Apothecary Capital and Pinnacle Ventures
Corthera Inc. San Mateo, Calif. 12/20 $23 Corthera closed a $23M Series C financing; new investor Caxton Advantage Life Sciences Fund joined Domain Associates and Kleiner, Perkins, Caufield & Byers in the financing round
Deltanoid Pharmaceuticals Inc. Madison, Wis. 12/18 $12 Deltanoid raised $12M in a Series B financing led by the Wisconsin Alumni Research Foundation that included Mason Wells and Venture Investors LLC, undisclosed corporations,-company founders and angel investors
Fovea Pharmaceuticals SA Paris 12/12 €30 ($44) Fovea raised $44M in a Series B round led by Forbion Capital Partners; they were joined by Sofinnova Partners, Abingworth, GIMV, the WellCome Trust and Credit Agricole Private Equity
Fundamental Applied Biology Menlo Park, Calif. 12/10 $21 Fundamental Applied Biology raised $21M in a Series B round co-led by SV Life Sciences and Alta Partners
Innocoll Inc. Ashburn, Va. 12/17 $30 Innocoll raised $30M through a placement of convertible preferred stock; the financing was led by Camulos Capital LP, NewSmith Asset Management LLP and Morgan Stanley & Co. Inc.
LineaGen Inc. Salt Lake City 12/19 $5.8 LineaGen closed a $5.8M Series A round led by vSpring Capital and Sanderling Biomedical Ventures, with participation by Mesa Verde Venture Partners
Lytix Biopharma Tromso, Norway 12/20 NOK50

($8.9)

Lytix raised $8.9M in a placement oversubscribed by Norwegian institutional and private investors
Pantec Biosolutions AG Ruggell, Liechtenstein 12/12** CHF6.3 ($5.6) Pantec raised $5.6M in a first closing of a Series A round
Pharnext Paris 12/12** €2.5 ($3.68) Pharnext raised $3.68M in seed funding from Truffle Capital
PregLem SA Geneva 12/4 CHF36 ($32.2) PregLem closed a Series B round led by Sofin-nova Ventures, with participation from returning investors Sofinnova Partners, MVM Life Science Partners LLP and NeoMed Management
Revance Therapeutics Inc. Mountainview, Calif. 12/12 $43.2 Medicis made a $20M equity investment in Revance as part of the Series C financing; other investors were Essex Woodlands, Healthcare Ventures, Vivo Ventures, Technology Partners Shepherd Ventures and Palo Alto Investors; Leerink Swann LLC acted as sole placement agent
Santaris Pharma AS Horsholm, Denmark 12/18 €20.4 ($29.4) Santaris raised $29.4M in an investment round led by Gilde Healthcare Partners BV
TcLand Expression SA Paris 12/19** €8.2 ($11.8) TcLand raised $11.8M in a Series A round led by Auriga Partners, and included investments by the Quest for Growth Privak fund managed by Quest Management NV, Beviguen, Debiopharm Group and Genzyme Ventures

Notes:

Currency conversions are based on exchange rates at the time of the deal.

** Denotes the date the item ran in BioWorld International. ND = Not disclosed.